Recent research has focused on the utility of cell free DNA (cfDNA) in serum and plasma for
clinical application, especially in oncology. The literature holds promise of cfDNA as a …

Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the mainstay treatment for
locally advanced rectal cancer. Variable degrees of tumor regression are observed after …

The recent understanding of tumour heterogeneity and cancer evolution in response to
therapy has raised questions about the value of historical or single site biopsies for guiding …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are current
treatments for advanced non-small cell lung cancer (NSCLC) harboring activating EGFR …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
death in the industrialized world. Despite progress in the understanding of the molecular …

Intratumour heterogeneity complicates biomarker discovery and treatment personalization,
and pervasive cancer evolution is a key mechanism leading to therapy failure and patient …

Gliomas are a common adult central nervous system tumor, and glioblastoma (GBM), which
has a poor prognosis, is the most lethal of all gliomas. The overall survival of GBM patients is …

Background Regorafenib, a multi-kinase inhibitor, is used in the treatment of patients with
metastatic colorectal cancer refractory to standard therapy. However, this benefit was limited …

Liver cancer has become the second cause of cancer-related death worldwide. Most
patients are still diagnosed at intermediate or advanced stage, where potentially curative …

Many methods have been developed for DNA integrity assessment including
electrophoresis-based procedures, quantitative PCR, and, more recently, microfluidics …